Terminated PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05272813

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Conditions Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions MS-553

Updated 7 times since 2022 Last updated: Jul 16, 2024 Started: Apr 28, 2022 Primary completion: Nov 28, 2023 Completion: Nov 28, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study is terminated due to major protocol revisions.

A PHASE1/PHASE2 clinical study on Lymphocytic Leukemia and Small Lymphocytic Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. and has accumulated 7 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Status: Recruiting → Terminated
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

May 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Apr 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Data source: MingSight Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China